Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative…

By Dr. Matthew Watson

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –

Originally posted here:
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative...

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - June 3rd, 2025
Abivax Presents First Quarter 2025 Financial Results - June 3rd, 2025
Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference - June 3rd, 2025
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - June 3rd, 2025
Vaxart Announces Adjournment of Annual Meeting of Stockholders - June 3rd, 2025
Sernova Appoints Jonathan Rigby as Interim Chair - June 3rd, 2025
Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes - June 3rd, 2025
Harvard Bioscience Appoints John Duke to Board of Directors - June 3rd, 2025
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3rd, 2025
Quest PharmaTech Provides Corporate Update - June 3rd, 2025
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - June 3rd, 2025
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - June 3rd, 2025
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - June 3rd, 2025
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - June 3rd, 2025
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - June 3rd, 2025
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference - June 3rd, 2025
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease - June 3rd, 2025
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer - June 3rd, 2025
Addex Convenes Annual General Meeting 2025 - June 3rd, 2025
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 - May 26th, 2025
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - May 26th, 2025
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of... - May 26th, 2025
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 - May 26th, 2025
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting - May 26th, 2025
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - May 26th, 2025
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer - May 26th, 2025
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd. - May 26th, 2025
Boundless Bio Announces Portfolio Prioritization and Runway Extension - May 26th, 2025
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year;... - May 26th, 2025
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - May 26th, 2025
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - May 26th, 2025
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - May 26th, 2025
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F - May 26th, 2025
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - May 26th, 2025
Polyrizon Announces Receipt of Nasdaq Delisting Notice - May 26th, 2025
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant... - May 26th, 2025
ZLNA – Issuance of shares through set-off of option exercise fee - May 26th, 2025
Guerbet : Changes in the composition of the Guerbet board of directors. - May 26th, 2025
Chair of Sernova Biotherapeutics Resigns - May 26th, 2025
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting - May 18th, 2025
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - May 18th, 2025
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates - May 18th, 2025
Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award - May 18th, 2025
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025 - May 18th, 2025
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - May 18th, 2025
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform - May 18th, 2025
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - May 18th, 2025
BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement - May 18th, 2025
Transactions of Managers and Closely Associated Persons - May 18th, 2025
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - May 18th, 2025
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the... - May 18th, 2025
TestoPrime Reviews Side Effects (INVESTIGATED) Is This Testosterone Booster Safe? (Ingredients, Results & Where to Buy) - May 18th, 2025
BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer - May 18th, 2025
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition - May 18th, 2025
Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm - May 18th, 2025
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the... - May 18th, 2025
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF... - May 18th, 2025
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - May 6th, 2025
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - May 6th, 2025
uniQure to Announce First Quarter 2025 Financial Results - May 6th, 2025
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - May 6th, 2025
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 - May 6th, 2025
FibroGen to Report First Quarter 2025 Financial Results - May 6th, 2025
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - May 6th, 2025
Context Therapeutics Announces Chief Medical Officer Transition - May 6th, 2025
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - May 6th, 2025
Certara Reports First Quarter 2025 Financial Results - May 6th, 2025
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - May 6th, 2025
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - May 6th, 2025
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET - May 6th, 2025
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of... - May 6th, 2025
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company - May 6th, 2025
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with... - May 6th, 2025
argenx to Present at BofA Securities 2025 Health Care Conference - May 6th, 2025
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity - May 6th, 2025
Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy - May 6th, 2025
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation - May 6th, 2025
Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa - April 23rd, 2025

Global News Feed commento

Comments Off | data

June 3rd, 2025

About... Dr. Matthew Watson

This author published 6252 posts in this site.

Comments are closed.

Previous post - Next post

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative…

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites